We recommend a long-term follow-up of these patients to investigate whether the tumor occurs or not and further research to elucidate the differential tumorigenic effects of IL-17 inhibitors in treatment of psoriatic arthritis and ankylosing spondylitis. Here, IL17A is linked to ankylosing spondylitis.